• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

22q11.2 Deletion Syndrome: Long-Term Mortality Risks and Outcomes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • 22q11.2 deletion syndrome (22q11.2DS) is the most common microdeletion syndrome, and affects an estimated 1 in 3000 to 4000 live births
  • Due to major medical advances, individuals with 22q11.2DS may live in to adulthood, but long-term outcomes are limited
  • Van et al. (Genetics in Medicine, 2019) sought to determine the impact of 22q11.2DS on life expectancy 

METHODS:

  • Prospective case-control design
  • Participants
    • Cases: Well-characterized adults (age ≥17 years) with 22q11.2DS
    • Controls: Unaffected siblings and parents of the adults with 22q11.2DS
  • Primary outcomes
    • All-cause mortality and survival

RESULTS:

  • 309 individuals with 22q11.2DS

Predictors of Mortality

  • 22q11.2DS and major congenital heart disease (CHD) were significant independent predictors of mortality for adults with 22q11.2DS vs their siblings
    • 22q11.2DS: hazard ratio [HR] 8.86 (95% CI, 2.87–27.37)
    • CHD: HR 5.03 (95% CI, 2.27–11.17)
  • Intellectual disability and psychotic illness were not predictors of mortality

Deaths

  • 31 deaths | 30 with parental data
  • Median age: 46.4 years (range 18.1–68.6)
  • Lower survival in adults with 22q11.2DS vs unaffected siblings (p < 0.0001)
  • Relationship to parental survival
    • Died while both parents living: 43.3%
    • Died while one parent was still living: 33.3%
    • Outlived both parents: 23.3%
  • Probability of survival with major CHD
    • To age 40: 82%
    • To age 50: 63%
  • Probability of survival without major CHD
    • To age 40: 98%
    • To age 50: 85%

CONCLUSION:

  • Both 22q11.2DS and associated severe forms of CHD both contribute to a lower life expectancy vs control group (family members)
  • A substantial number of individuals with 22q11.2DS outlived both parents  

Learn More – Primary Sources:

All-cause mortality and survival in adults with 22q11.2 deletion syndrome

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

22q11.2 Deletion Syndrome – Key Clinical Highlights
Is Prenatal Microarray Use Justified as a First Tier Test for Fetal Congenital Heart Disease?
The Use of Microarrays in the Prenatal and Postnatal Setting – Current Professional Guidelines
Microarrays and Microdeletions: Key Concepts Summarized

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site